Literature DB >> 27748073

Reply.

Lindsay E Nyhoff1, Leslie J Crofford1, Peggy L Kendall1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27748073      PMCID： PMC5274625          DOI： 10.1002/art.39957

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   10.995


× No keyword cloud information.
  25 in total

1.  The health status and quality of life of adults with X-linked agammaglobulinemia.

Authors:  Vanessa Howard; Jeffrey M Greene; Savita Pahwa; Jerry A Winkelstein; John M Boyle; Mehmet Kocak; Mary Ellen Conley
Journal:  Clin Immunol       Date:  2005-12-22       Impact factor: 3.969

2.  Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk.

Authors:  Xingguang Liu; Zhenzhen Zhan; Dong Li; Li Xu; Feng Ma; Peng Zhang; Hangping Yao; Xuetao Cao
Journal:  Nat Immunol       Date:  2011-03-27       Impact factor: 25.606

3.  X-linked agammaglobulinemia in two siblings with a novel mutation in the BTK gene who presented with polyarticular juvenile idiopathic arthritis.

Authors:  T Patiroglu; H H Akar; Z Gunduz; S Sisko; Y Y Ng
Journal:  Scand J Rheumatol       Date:  2015       Impact factor: 3.641

Review 4.  Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.

Authors:  Jan A Burger
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

5.  B cells in patients with X-linked agammaglobulinemia.

Authors:  M E Conley
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

6.  Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation.

Authors:  Vassilios Lougaris; Manuela Baronio; Massimiliano Vitali; Giacomo Tampella; Marco Cattalini; Laura Tassone; Annarosa Soresina; Raffaele Badolato; Alessandro Plebani
Journal:  J Allergy Clin Immunol       Date:  2014-03-04       Impact factor: 10.793

7.  RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.

Authors:  Daigen Xu; Yong Kim; Jennifer Postelnek; Minh Diem Vu; Dong-Qing Hu; Cheng Liao; Mike Bradshaw; Jonathan Hsu; Jun Zhang; Achal Pashine; Dinesh Srinivasan; John Woods; Anita Levin; Alison O'Mahony; Timothy D Owens; Yan Lou; Ronald J Hill; Satwant Narula; Julie DeMartino; Jay S Fine
Journal:  J Pharmacol Exp Ther       Date:  2012-01-06       Impact factor: 4.030

8.  Bruton's Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice but Fails to Block Immune Complex-Mediated Inflammatory Arthritis.

Authors:  Lindsay E Nyhoff; Bridgette L Barron; Elizabeth M Johnson; Rachel H Bonami; Damian Maseda; Benjamin A Fensterheim; Wei Han; Timothy S Blackwell; Leslie J Crofford; Peggy L Kendall
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

9.  The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.

Authors:  Betty Y Chang; Min Mei Huang; Michelle Francesco; Jun Chen; Jeremy Sokolove; Padmaja Magadala; William H Robinson; Joseph J Buggy
Journal:  Arthritis Res Ther       Date:  2011-07-13       Impact factor: 5.156

10.  Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways.

Authors:  A B Satterthwaite; C A Lowell; W N Khan; P Sideras; F W Alt; O N Witte
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.